Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Lawsuits Filed Against OCGN, CRMD and ARDX - Jakubowitz Law Pursues Shareholders Claims By: Jakubowitz Law via AccessWire August 11, 2021 at 12:10 PM EDT NEW YORK, NY / ACCESSWIRE / August 11, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.Ocugen, Inc. (NASDAQ:OCGN)CONTACT JAKUBOWITZ ABOUT OCGN:https://claimyourloss.com/securities/ocugen-inc-loss-submission-form/?id=18450&from=1Class Period: February 2, 2021 - June 10, 2021Lead Plaintiff Deadline: August 17, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.CorMedix Inc. (NASDAQ:CRMD)CONTACT JAKUBOWITZ ABOUT CRMD:https://claimyourloss.com/securities/cormedix-inc-loss-submission-form/?id=18450&from=1Class Period: July 8, 2020 - May 13, 2021Lead Plaintiff Deadline: September 20, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Ardelyx, Inc. (NASDAQ:ARDX)CONTACT JAKUBOWITZ ABOUT ARDX:https://claimyourloss.com/securities/ardelyx-inc-loss-submission-form/?id=18450&from=1Class Period: August 6, 2020 - July 19, 2021Lead Plaintiff Deadline: September 28, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887SOURCE: Jakubowitz LawView source version on accesswire.com: https://www.accesswire.com/659345/Lawsuits-Filed-Against-OCGN-CRMD-and-ARDX--Jakubowitz-Law-Pursues-Shareholders-Claims Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Lawsuits Filed Against OCGN, CRMD and ARDX - Jakubowitz Law Pursues Shareholders Claims By: Jakubowitz Law via AccessWire August 11, 2021 at 12:10 PM EDT NEW YORK, NY / ACCESSWIRE / August 11, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.Ocugen, Inc. (NASDAQ:OCGN)CONTACT JAKUBOWITZ ABOUT OCGN:https://claimyourloss.com/securities/ocugen-inc-loss-submission-form/?id=18450&from=1Class Period: February 2, 2021 - June 10, 2021Lead Plaintiff Deadline: August 17, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the information submitted to the U.S. Food and Drug Administration ("FDA") was insufficient to support an Emergency Use Authorization ("EUA"), (ii) Ocugen would not file an EUA with the FDA, (iii) as a result of the foregoing, the Company's financial statements, as well as Defendants' statements about Ocugen's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.CorMedix Inc. (NASDAQ:CRMD)CONTACT JAKUBOWITZ ABOUT CRMD:https://claimyourloss.com/securities/cormedix-inc-loss-submission-form/?id=18450&from=1Class Period: July 8, 2020 - May 13, 2021Lead Plaintiff Deadline: September 20, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) deficiencies existed with respect to an investigational drug product, DefenCath's, manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the Food and Drug Administration was unlikely to approve the DefenCath new drug application for catheter-related bloodstream infections in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.Ardelyx, Inc. (NASDAQ:ARDX)CONTACT JAKUBOWITZ ABOUT ARDX:https://claimyourloss.com/securities/ardelyx-inc-loss-submission-form/?id=18450&from=1Class Period: August 6, 2020 - July 19, 2021Lead Plaintiff Deadline: September 28, 2021The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: 1) the Company overstated the likelihood that tenapanor would be approved by the Food and Drug Administration ("FDA"); and 2) Defendants possessed, were in control over, and as a result, knew that the data submitted to support the New Drug Application was insufficient in that it showed a lack of clinical relevance of the drug's treatment effect, making it foreseeably likely that the FDA would not approve the drug.Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.CONTACT:JAKUBOWITZ LAW1140 Avenue of the Americas9th FloorNew York, New York 10036T: (212) 867-4490F: (212) 537-5887SOURCE: Jakubowitz LawView source version on accesswire.com: https://www.accesswire.com/659345/Lawsuits-Filed-Against-OCGN-CRMD-and-ARDX--Jakubowitz-Law-Pursues-Shareholders-Claims
